[go: up one dir, main page]

TN2013000414A1 - 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma - Google Patents

4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma

Info

Publication number
TN2013000414A1
TN2013000414A1 TNP2013000414A TN2013000414A TN2013000414A1 TN 2013000414 A1 TN2013000414 A1 TN 2013000414A1 TN P2013000414 A TNP2013000414 A TN P2013000414A TN 2013000414 A TN2013000414 A TN 2013000414A TN 2013000414 A1 TN2013000414 A1 TN 2013000414A1
Authority
TN
Tunisia
Prior art keywords
benzimidazol
methylpiperazin
fluoro
amino
quinoli
Prior art date
Application number
TNP2013000414A
Other languages
English (en)
Inventor
Michael Shi
Michael Wick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000414(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000414A1 publication Critical patent/TN2013000414A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2013000414A 2011-05-19 2013-10-11 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma TN2013000414A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487939P 2011-05-19 2011-05-19
PCT/US2012/038490 WO2012158994A1 (fr) 2011-05-19 2012-05-18 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique

Publications (1)

Publication Number Publication Date
TN2013000414A1 true TN2013000414A1 (en) 2015-03-30

Family

ID=46168643

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000414A TN2013000414A1 (en) 2011-05-19 2013-10-11 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma

Country Status (18)

Country Link
US (1) US20150182525A1 (fr)
EP (1) EP2709729A1 (fr)
JP (1) JP2014515353A (fr)
KR (1) KR20140023358A (fr)
CN (1) CN103547315A (fr)
AU (1) AU2012255148A1 (fr)
BR (1) BR112013029246A2 (fr)
CA (1) CA2834699A1 (fr)
CL (1) CL2013003306A1 (fr)
IL (1) IL229073A0 (fr)
MA (1) MA35156B1 (fr)
MX (1) MX2013013437A (fr)
PH (1) PH12013502099A1 (fr)
RU (1) RU2013156378A (fr)
SG (1) SG194445A1 (fr)
TN (1) TN2013000414A1 (fr)
WO (1) WO2012158994A1 (fr)
ZA (1) ZA201307411B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
KR20220025196A (ko) 2012-09-07 2022-03-03 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (zh) 2019-10-14 2023-03-21 因赛特公司 作为fgfr抑制剂的双环杂环
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
BRPI0607285A2 (pt) * 2005-01-27 2009-08-25 Novartis Vaccines & Diagnostic tratamento de tumores com metástases
PT1885187E (pt) * 2005-05-13 2013-12-16 Novartis Ag Métodos para o tratamento de cancro resistente a fármacos
EP2270000B1 (fr) 2005-05-23 2015-07-29 Novartis AG Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
AU2006272759B2 (en) 2005-07-22 2012-01-12 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
MA34106B1 (fr) * 2010-04-16 2013-03-05 Novartis Ag Combinaison de composés organiques

Also Published As

Publication number Publication date
JP2014515353A (ja) 2014-06-30
US20150182525A1 (en) 2015-07-02
MA35156B1 (fr) 2014-06-02
PH12013502099A1 (en) 2017-10-25
CN103547315A (zh) 2014-01-29
ZA201307411B (en) 2014-06-25
MX2013013437A (es) 2013-12-06
AU2012255148A1 (en) 2013-11-07
KR20140023358A (ko) 2014-02-26
CL2013003306A1 (es) 2014-07-11
RU2013156378A (ru) 2015-06-27
IL229073A0 (en) 2013-12-31
SG194445A1 (en) 2013-12-30
CA2834699A1 (fr) 2012-11-22
NZ616345A (en) 2015-10-30
WO2012158994A1 (fr) 2012-11-22
BR112013029246A2 (pt) 2017-02-14
EP2709729A1 (fr) 2014-03-26

Similar Documents

Publication Publication Date Title
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2015017964A (es) Inhibidores de bromodominio.
NZ706836A (en) Methods of treating cancer
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MY165826A (en) Pharmaceutical composition
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2016002302A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
HK1258235A1 (zh) 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
UA115250C2 (uk) Фармацевтичні комбінації
IL229424A0 (en) Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
PH12014500973A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies